K-Pio 15 Tablet contains Pioglitazone 15 mg, an oral antihyperglycemic agent belonging to the thiazolidinedione class, indicated for the management of type 2 diabetes mellitus. Pioglitazone acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor-gamma (PPAR-γ), which modulates the transcription of insulin-responsive genes involved in glucose and lipid metabolism. This mechanism enhances peripheral glucose uptake and utilization, thereby improving glycemic control in patients with insulin resistance. K-Pio 15 is typically prescribed as monotherapy or in combination with other antidiabetic agents such as metformin or sulfonylureas when diet and exercise alone are insufficient to achieve adequate glycemic control. The tablet is administered orally once daily, with or without food, as directed by a healthcare professional. Common adverse effects may include weight gain, edema, and increased risk of upper respiratory tract infections. It is contraindicated in patients with heart failure, active liver disease, or known hypersensitivity to pioglitazone. Regular monitoring of liver function tests and cardiovascular status is recommended during therapy. K-Pio 15 should be used cautiously in patients with a history of bladder cancer or osteoporosis. Proper adherence to prescribed dosage and lifestyle modifications is essential to optimize therapeutic outcomes.